CureVac NV CVAC.OQ, CVAC.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Tuebingen Baden-wuerttemberg-based company is expected to report a 529.5% increase in revenue to €103.764 million from €16.48 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for CureVac NV is for earnings of 56 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for CureVac NV is $7.00, above its last closing price of $2.83.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.31 | -0.26 | -0.32 | Missed | -20.8 |
Jan. 1 2024 | -0.24 | -0.23 | -0.31 | Missed | -36 |
Dec. 31 2023 | -0.18 | -0.39 | Missed | -110.8 | |
Sep. 30 2023 | -0.18 | -0.23 | -0.22 | Beat | 3.5 |
Jan. 1 0001 | -0.24 | -0.24 | -0.30 | Missed | -25 |
Mar. 31 2023 | -0.34 | -0.34 | -0.27 | Beat | 20.6 |
Dec. 31 2022 | -0.31 | -0.60 | Missed | -95.1 | |
Sep. 30 2022 | -0.27 | -0.27 | -0.25 | Beat | 6.3 |
This summary was machine generated November 8 at 16:58 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments